ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer

Chest

Volumn 127, Issue 3, 2005, Pages 978-983

  Simon, George R ^a   Sharma, Swati ^a   Cantor, Alan ^a   Smith, Prudence ^a   Bepler, Gerald ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Adenocarcinoma; Non small cell lung cancer and prognosis; Nuclear excision repair genes; Squamous cell carcinoma

Indexed keywords

EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; LIQUID NITROGEN; RNA 18S; DNA BINDING PROTEIN; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CORRELATION ANALYSIS; DNA REPAIR; EXCISION REPAIR; FEMALE; GENE AMPLIFICATION; GENOMIC INSTABILITY; HUMAN; HUMAN TISSUE; INTRON; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECURRENCE RISK; RELAPSE; REVERSE TRANSCRIPTION; RNA TRANSCRIPTION; STATISTICAL SIGNIFICANCE; GENETICS; LUNG TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DNA REPAIR; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL RATE;

EID: 15844372318     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.127.3.978     Document Type: Article

References (35)

1. Jemal A, Murray T, Samuels A, et al. Cancer statistics. CA Cancer J Clin 2003; 53:5-26
2. Page NC, Read WL, Tierney RM, et al. The epidemiology of small cell lung cancer [abstract]. Proc ASCO 2002; 21:305a
3. Bepler G, Gautam A, McIntyre LN, et al. Prognostic significance of molecular genetic aberrations on chromosome segment 11p15.5 in non-small cell lung cancer. J Clin Oncol 2002; 20:1353-1360
4. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997; 111:1710-1717
5. Mountain CF, Dresler CM. Regional lymph node classification for lung cancer staging. Chest 1997; 111:1718-1723
6. Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group. Lancet 1998; 352:257-263
7. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials; Non-small Cell Lung Cancer Collaborative Group. BMJ 1995; 311:899-909
8. Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350:351-360
9. Hoeijmakers JH. Nucleotide excision repair: II. From yeast to mammals. Trends Genet 1993; 9:211-217
10. van Duin M, de Wit J, Odijk H, et al. Molecular characterization of the human excision repair gene ERCC-1: cDNA cloning and amino acid homology with the yeast DNA repair gene RAD10. Cell 1986; 44:913-923
11. Tomkinson AE, Bardwell AJ, Bardwell L, et al. Yeast DNA repair and recombination proteins Rad1 and Rad10 constitute a single-stranded-DNA endonuclease. Nature 1993; 362: 860-862
12. Shirota Y, Stoehlmacher J, Brabender J, et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001; 19:4298-4304
13. Rouet P, Smih F, Jasin M. Introduction of double-strand breaks into the genome of mouse cells by expression of a rare-cutting endonuclease. Mol Cell Biol 1994; 14:8096-8106
14. Liang F, Han M, Romanienko PJ, et al. Homology-directed repair is a major double-strand break repair pathway in mammalian cells. Proc Natl Acad Sci U S A 1998; 95:5172-5177
15. Slebos RJ, Hruban RH, Dalesio O, et al. Relationship between K-ras oncogene activation and smoking in adenocarcinoma of the human lung. J Natl Cancer Inst 1991; 83:1024-1027
16. Carbone DP, Mitsudomi T, Chiba I, et al. p53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer: a preliminary report of LCSG 871. Chest 1994; 106:3778-3818
17. Schiller JH, Adak S, Feins RH, et al. Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy. J Clin Oncol 2001; 19:448-457
18. Rosell R, Pifarre A, Monzo M, et al. Reduced survival in patients with stage-I non-small-cell lung cancer associated with DNA-replication errors. Int J Cancer 1997; 74:330-334
19. Greatens TM, Niehans GA, Rubins JB, et al. Do molecular markers predict survival in non-small-cell lung cancer? Am J Respir Grit Care Med 1998; 157:1093-1097
20. Volm M, Hahn EW, Mattern J, et al. Five-year follow-up study of independent clinical and flow cytometric prognostic factors for the survival of patients with non-small cell lung carcinoma. Cancer Res 1988; 48:2923-2928
21. Fong KM, Zimmerman PV, Smith PJ. Microsatellite instability and other molecular abnormalities in non-small cell lung cancer. Cancer Res 1995; 55:28-30
22. Franklin WA, Veve R, Hirsch FR, et al. Epidermal growth factor receptor family in lung cancer and premalignancy. Semin Oncol 2002; 29:3-14
23. Rusch V, Klimstra D, Venkatraman E, et al. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor α is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res 1997; 3:515-522
24. Pezzella F, Turley H, Kuzu I, et al. bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med 1993; 329:690-694
25. Volm M, Koomagi R, Mattern J. Prognostic value of p16INK4A expression in lung adenocarcinoma. Anticancer Res 1998; 18:2309-2312
26. Brambilla E, Moro D, Gazzeri S, et al. Alterations of expression of Rb, p16(INK4A) and cyclin D1 in non-small cell lung carcinoma and their clinical significance. J Pathol 1999; 188:351-360
27. Robert C, Bolon I, Gazzeri S, et al. Expression of plasminogen activator inhibitors 1 and 2 in lung cancer and their role in tumor progression. Clin Cancer Res 1999; 5:2094-2102
28. Vansteenkiste JF, Stroobants SG, Dupont PJ, et al. Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases; Leuven Lung Cancer Group. J Clin Oncol 1999; 17:3201-3206
29. Cheng L, Spitz MR, Hong WK, et al. Reduced expression levels of nucleotide excision repair genes in lung cancer: a case-control analysis. Carcinogenesis 2000; 21:1527-1530
30. Metzger R, Leichman CG, Danenberg KD, et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 1998; 16:309-316
31. Dabholkar M, Bostick-Bruton F, Weber C, et al. ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst 1992; 84:1512-1517
32. Metzger R, Schneider PM, Baldus SE, et al. Quantitative ERCC1 RNA expression identifies non-response to cis-platinum based neoadjuvant radiochemotherapy for esophageal cancer [abstract]. Proc ASCO 2001; 20:130a
33. Lord RV, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002; 8:2286-2291
34. Melton DW, Ketchen AM, Nunez F, et al. Cells from ERCC1-deficient mice show increased genome instability and a reduced frequency of S-phase-dependent illegitimate chromosome exchange but a normal frequency of homologous recombination. J Cell Sci 1998; 111:395-404
35. Li Q, Yu JJ, Mu C, et al. Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells. Anticancer Res 2000; 20:645-652